Sequence generation
malignancy, tumor, CRF
TUMOR, CRF
Patients will be prospectively included in the study in 2 steps:Patients will first be registered, after check of eligibility criteria and signature of the informed consent form, before any trial related procedure.Randomization (and validation of the inclusion) will then be performed: (1) before surgery for patients with malignant cytology (Bethesda 6) or (2) in the operating room, after total thyroidectomy and after confirmation of malignancy by intra-operative frozen section analysis for patients with suspicious cytology (Bethesda 5). Randomization will be performed online or by fax with the Trial Master program.Randomization will be performed online or by fax with the Trial Master program. Patients will be randomly allocated to one of the two treatment groups, based on blocks of participants, stratified by tumor size (cT1b vs cT2) and site (to ensure a balance between the treatment groups at each site). The blocking and stratification measures will not be revealed to those enrolling patients or those allocating the interventions.Once randomized, patients must be treated as defined in the assigned group and cannot change.Inclusion/registration and randomization will be performed online or by fax, using the TrialMaster program, and electronically centralized by the Biostatistics and Epidemiology Unit at Gustave Roussy. A fax or an internet access in the operating room or at proximity is then mandatory. In case of any kind of problem, the investigator will contact the study data manager.The data manager email address, phone, and fax number will be notified in the CRF. In case of any emergency or in the absence of the study data manager, an on-duty data manager will available.